What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Histone Methylation: Types, Mechanisms, and Roles in Gene Regulation

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Histone Methylation

Eukaryotic genomic DNA is packaged into chromatin, a dynamic polymer whose fundamental repeating unit is the nucleosome. Each nucleosome consists of approximately 147 base pairs of DNA wrapped around a Histone Octamer composed of two copies each of the core histone proteins H2A, H2B, H3, and H4. These proteins are small, highly basic polypeptides that not only organize DNA but also serve as platforms for a vast array of post-translational modifications (PTMs) that regulate genome function. Among these modifications, histone methylation is one of the most chemically stable and functionally diverse.

Histone methylation refers to the covalent addition of one, two, or three methyl groups to specific nitrogen atoms on the side chains of lysine or arginine residues located predominantly in the N-terminal tails of histones, though methylation also occurs within the globular core domains. Unlike histone acetylation, which neutralizes the positive charge of lysine and generally correlates with open chromatin, methylation does not alter the net charge of the residue. Instead, its effects are mediated primarily through the recruitment of effector proteins that recognize methylated marks and subsequently influence chromatin structure, transcription, DNA repair, and replication.

The study of histone methylation is central to the Histone Code hypothesis, which posits that combinations of PTMs on histone tails act as a regulatory language read by specific protein modules. Methylation marks can be stable across cell divisions, providing a mechanism for epigenetic inheritance, yet they are also enzymatically reversible, allowing dynamic responses to developmental and environmental cues. This dual nature places histone methylation at the heart of gene regulation, cellular differentiation, and disease pathogenesis.

Types of Histone Methylation

Histone methylation occurs on two types of amino acid side chains: lysine and arginine. The chemical nature of the modification—mono-, di-, or trimethylation—determines the structural and functional outcome, as each methylation state creates a distinct binding surface for reader proteins.

Lysine Methylation

Lysine residues possess a primary amine (ε-amino group) on their side chains that can accept up to three methyl groups, yielding monomethylated (me1), dimethylated (me2), and trimethylated (me3) forms. Each addition of a methyl group increases the hydrophobicity and basicity of the side chain and alters its hydrogen-bonding capacity. The methylation state is not merely a quantitative difference; it is functionally distinct. For example, H3K4me1 marks enhancers, H3K4me2 is found at promoters and enhancers, and H3K4me3 is enriched at active gene promoters. These marks are deposited by different enzyme complexes and read by different effector proteins.

The major lysine methylation sites on histone H3 include K4, K9, K27, K36, and K79; on H4, K20 is the primary site. Each site is associated with a characteristic transcriptional outcome. H3K4me3 and H3K36me3 are activating marks, whereas H3K9me3 and H3K27me3 are repressive. H3K79me2/3 is generally associated with active transcription, and H4K20me1 is linked to both gene activation and DNA damage response, while H4K20me3 is associated with constitutive heterochromatin.

Arginine Methylation

Arginine residues contain a guanidinium group with two terminal nitrogen atoms that can be methylated in three configurations: monomethylation (MMA), asymmetric dimethylation (aDMA), and symmetric dimethylation (sDMA). Asymmetric dimethylation places both methyl groups on the same terminal nitrogen, while symmetric dimethylation places one methyl group on each terminal nitrogen. These distinct configurations are generated by different families of protein arginine methyltransferases (PRMTs) and are recognized by different reader proteins.

The most studied arginine methylation sites are H3R2, H3R8, H3R17, H3R26, and H4R3. H3R2me2a (asymmetric) is generally repressive and antagonizes H3K4me3, whereas H3R2me2s (symmetric) is associated with active transcription. H4R3me2a is activating at some promoters, while H4R3me2s can be repressive. Arginine methylation is often dynamic during transcriptional activation, particularly at hormone-responsive genes, where it facilitates the recruitment of the transcriptional machinery.

Histone Methyltransferases and Demethylases

The addition and removal of methyl groups are catalyzed by two opposing classes of enzymes: histone methyltransferases (HMTs) and histone demethylases (HDMs). These enzymes exhibit strict substrate specificity, targeting particular residues and specific methylation states.

SET Domain Enzymes

The majority of lysine methyltransferases contain a conserved catalytic domain called SET (Suppressor of variegation, Enhancer of zeste, Trithorax), named after three Drosophila genes. The SET domain adopts a conserved fold that positions the lysine substrate and the cofactor S-adenosylmethionine (SAM) in a productive orientation. SET domain enzymes are highly specific; for example, the mixed-lineage leukemia (MLL) family members catalyze H3K4 methylation, the SUV39 family (SUV39H1, SUV39H2) and G9a/GLP catalyze H3K9 methylation, and the Polycomb repressive complex 2 (PRC2), containing the catalytic subunit EZH2, catalyzes H3K27 methylation.

SET domain enzymes often function within multisubunit complexes that regulate their activity and targeting. For instance, PRC2 contains the accessory proteins EED and SUZ12, which are required for full enzymatic activity and for recognition of pre-existing H3K27me3 marks, enabling propagation of the repressive state. Similarly, the MLL complexes contain WDR5, RbBP5, and ASH2L, which are essential for H3K4 methylation activity.

DOT1L

DOT1L (disruptor of telomeric silencing 1-like) is the sole non-SET domain lysine methyltransferase. It methylates H3K79, a residue located in the globular domain of histone H3 rather than in the N-terminal tail. DOT1L uses a different catalytic mechanism, related to the Rossmann-fold family of methyltransferases, and its activity is dependent on the presence of H2B monoubiquitination at lysine 123 (in yeast) or lysine 120 (in mammals). DOT1L is primarily associated with active transcription and is required for normal development, particularly of the heart and hematopoietic system.

LSD1 and JmjC Demethylases

Histone demethylases reverse methylation marks. The first discovered demethylase, LSD1 (lysine-specific demethylase 1, also known as KDM1A), is a flavin adenine dinucleotide (FAD)-dependent amine oxidase that removes methyl groups from H3K4me1/me2 and, in certain contexts, H3K9me1/me2. LSD1 cannot demethylate trimethylated substrates because its mechanism requires a protonated nitrogen on the substrate.

The Jumonji C (JmjC) domain-containing demethylases (KDMs) constitute a larger family of Fe(II)- and α-ketoglutarate-dependent dioxygenases. These enzymes can remove mono-, di-, and trimethyl marks from lysine and arginine residues. Examples include KDM2A/B (H3K36me1/me2), KDM3A (H3K9me1/me2), KDM4A-D (H3K9me2/me3 and H3K36me2/me3), KDM5A-D (H3K4me2/me3), and KDM6A/B (H3K27me2/me3). The JmjC enzymes use molecular oxygen and α-ketoglutarate to hydroxylate the methyl group, which then spontaneously releases as formaldehyde.

Arginine demethylation is less well characterized. The JmjC enzyme KDM3A (JMJD1A) and the peptidylarginine deiminase PADI4 have been implicated in converting arginine methylation to citrulline, although PADI4 does not restore the unmodified arginine. The reversibility of arginine methylation remains an area of active investigation.

Mechanism of Histone Methylation

The biochemical mechanism of histone methylation is a nucleophilic substitution reaction in which the ε-amino group of a lysine or the guanidinium group of an arginine attacks the methyl group of SAM.

Catalytic Mechanism

For SET domain enzymes, the reaction proceeds through an SN2 mechanism. The deprotonated lysine ε-amino group acts as a nucleophile, attacking the methyl carbon of SAM. This displaces S-adenosylhomocysteine (SAH) and transfers the methyl group to the lysine side chain. The SET domain contains a conserved tyrosine residue that positions the lysine and stabilizes the transition state. The reaction requires the lysine to be in a deprotonated state, which is facilitated by the enzyme's active site environment.

For DOT1L, the mechanism is similar but the active site architecture differs. DOT1L uses a catalytic glutamate to activate the lysine substrate, and its substrate-binding channel accommodates the globular H3K79 residue.

S-adenosylmethionine (SAM) Role

SAM is the universal methyl donor for all histone methyltransferases. SAM is synthesized from methionine and ATP by methionine adenosyltransferase. In the methyltransferase reaction, SAM donates its activated methyl group, which is attached to a positively charged sulfonium ion, making it a highly reactive electrophile. After methyl transfer, SAM is converted to SAH, which is a potent product inhibitor of methyltransferases. Cellular SAH levels are regulated by SAH hydrolase, which cleaves SAH into homocysteine and adenosine, preventing feedback inhibition.

The concentration of SAM and the SAM/SAH ratio within the nucleus can influence methyltransferase activity. Disruptions in one-carbon metabolism, which affect SAM availability, have been linked to altered histone methylation patterns and disease states.

Effects on Chromatin Structure and Gene Expression

Histone methylation influences gene expression through two primary mechanisms: direct effects on chromatin compaction and, more importantly, the recruitment of effector proteins that remodel chromatin or regulate transcription.

Activating Marks (e.g., H3K4me3)

H3K4me3 is a hallmark of active gene promoters. It is recognized by proteins containing PHD (plant homeodomain) fingers, such as the transcriptional co-activator TAF3, which is part of the TFIID complex that initiates RNA polymerase II transcription. H3K4me3 also recruits the NURF chromatin remodeling complex via the BPTF subunit, which slides nucleosomes to expose promoter DNA. Additionally, H3K4me3 prevents the binding of repressive complexes, such as the NuRD complex, which would otherwise deacetylate histones and silence the locus.

H3K36me3 is enriched in the gene bodies of actively transcribed genes. It is deposited co-transcriptionally by SETD2, which associates with the elongating form of RNA polymerase II. H3K36me3 recruits the Rpd3S histone deacetylase complex in yeast (or its mammalian homologs), which removes acetylation marks from transcribed regions to prevent spurious transcription initiation from cryptic promoters within gene bodies.

Repressive Marks (e.g., H3K27me3)

H3K27me3 is a canonical repressive mark deposited by PRC2. This mark is recognized by the chromodomain of the Polycomb (CBX) proteins within the PRC1 complex. PRC1 then ubiquitinates H2A at lysine 119, which contributes to chromatin compaction and transcriptional repression. H3K27me3 also recruits the chromodomain protein HP1 in some contexts, although HP1 primarily recognizes H3K9me3.

H3K9me3 is the defining mark of constitutive heterochromatin, including centromeres, telomeres, and transposable elements. It is deposited by SUV39H1/2 and recognized by HP1 proteins (HP1α, HP1β, HP1γ) via their chromodomains. HP1 binding leads to chromatin compaction and the recruitment of additional SUV39 enzymes, creating a self-propagating loop that maintains heterochromatin across cell divisions. H3K9me3 also recruits the DNA methyltransferase DNMT3B, linking histone methylation to DNA methylation at repetitive elements.

The functional outcome of a methylation mark is highly context-dependent. For example, H3K4me1 is activating at enhancers but can be repressive at promoters. H3K9me1 is associated with active transcription at gene bodies, while H3K9me3 is repressive. The same mark can have opposite effects depending on the genomic location, the cell type, and the complement of reader proteins expressed.

Methods to Study Histone Methylation

Investigating histone methylation requires techniques that can detect specific marks at defined genomic loci or quantify global changes in methylation levels.

Chromatin Immunoprecipitation (ChIP)

ChIP is the standard method for mapping histone modifications to specific genomic regions. Cells are treated with formaldehyde to cross-link proteins to DNA, and chromatin is sheared by sonication or enzymatic digestion into fragments of approximately 200–600 base pairs. The chromatin is then immunoprecipitated with an antibody specific for a particular methylation mark, such as anti-H3K4me3. After reversing the cross-links and purifying the DNA, the enriched fragments are analyzed by quantitative PCR (ChIP-qPCR) or by high-throughput sequencing (ChIP-seq).

ChIP-seq requires careful controls, including an input sample (total chromatin before immunoprecipitation) and often a histone modification-independent antibody (e.g., anti-H3) to normalize for nucleosome density. Typical ChIP experiments use 1–10 million cells per immunoprecipitation, with 1–5 µg of antibody and incubation overnight at 4°C. The quality of the antibody is the single most critical factor; many commercial antibodies cross-react with other marks or fail to distinguish between methylation states.

Mass Spectrometry

Mass spectrometry (MS) provides an unbiased, global view of histone methylation. Histones are acid-extracted from cells, and the N-terminal tails are digested with trypsin or Arg-C to generate peptides of suitable size for MS analysis. The peptides are separated by liquid chromatography and analyzed by tandem mass spectrometry (LC-MS/MS). The mass shift of +14.016 Da per methyl group allows identification of the methylation state and the specific residue.

MS can quantify the relative abundance of different methylation states, including the distinction between mono-, di-, and trimethylation, and can identify novel methylation sites. However, MS requires specialized equipment and expertise, and it does not provide genomic localization information.

Antibody-Based Assays

Beyond ChIP, antibodies against specific methylation marks are used in several other assays. Western blotting with anti-methyl-histone antibodies can compare total levels of a mark across samples. Enzyme-linked immunosorbent assays (ELISAs) and dot blots provide similar information with higher throughput. Immunofluorescence microscopy using anti-methyl-histone antibodies reveals the spatial distribution of marks within the nucleus, such as the enrichment of H3K9me3 at pericentric heterochromatin or H3K27me3 at the inactive X chromosome.

A critical caveat for all antibody-based methods is that antibodies may recognize the methylated peptide in one context but fail to recognize it when the surrounding residues carry additional modifications. This "context effect" is a major source of artifacts in histone methylation studies.

Histone Methylation in Development and Disease

Histone methylation is essential for normal development and is frequently misregulated in human diseases, particularly cancer.

Stem Cell Differentiation

Pluripotent embryonic stem cells (ESCs) maintain a unique chromatin landscape characterized by "bivalent domains"—regions that carry both the activating H3K4me3 mark and the repressive H3K27me3 mark. These bivalent domains are found at developmental genes that are poised for activation upon differentiation. The Polycomb and Trithorax complexes maintain this poised state, and the resolution of bivalency toward either activation or repression is a key step in lineage commitment.

During differentiation, lineage-specific genes lose H3K27me3 and retain or increase H3K4me3, becoming actively transcribed, while genes for alternative lineages lose H3K4me3 and gain H3K27me3, becoming stably repressed. The balance between H3K4 and H3K27 methylation is regulated by the opposing activities of MLL complexes and PRC2, as well as by demethylases such as KDM5 (H3K4 demethylase) and KDM6 (H3K27 demethylase).

Cancer and Other Diseases

Mutations and dysregulation of histone methylation machinery are among the most common epigenetic alterations in cancer. EZH2, the catalytic subunit of PRC2, is overexpressed or mutated in many cancers, including lymphoma, prostate, and breast cancer. Activating mutations in EZH2 (e.g., Y641) increase H3K27me3 levels and promote aberrant silencing of tumor suppressor genes. Conversely, inactivating mutations in EZH2 occur in myeloid malignancies, indicating context-dependent roles.

The H3K4 methyltransferases MLL1 and MLL2 are frequent targets of chromosomal translocations in acute leukemias. These translocations create fusion proteins that retain the N-terminal DNA-binding domain of MLL but lose the SET domain, instead fusing to various partners such as AF4, AF9, or ENL. The resulting fusion proteins aberrantly activate genes such as HOXA9 and MEIS1, driving leukemogenesis.

Loss-of-function mutations in the H3K27 demethylase KDM6A (UTX) occur in multiple tumor types, and mutations in the H3K36 methyltransferase SETD2 are common in renal cell carcinoma and glioblastoma. Additionally, recurrent mutations in histone H3 itself—at lysine 27 (H3K27M) and lysine 36 (H3K36M)—are found in pediatric gliomas and chondroblastomas, respectively. These "oncohistones" act in a dominant-negative manner, inhibiting the corresponding methyltransferases and globally reducing H3K27me3 or H3K36me3 levels.

Beyond cancer, histone methylation dysregulation is implicated in neurodevelopmental disorders such as Kabuki syndrome (mutations in KMT2D and KDM6A), intellectual disability (mutations in EHMT1, which encodes GLP), and Huntington's disease, where altered H3K9 and H3K27 methylation contribute to neuronal dysfunction.

Common Pitfalls and Misconceptions

Students frequently encounter several conceptual difficulties when studying histone methylation.

Methylation vs. Acetylation

The most common error is conflating histone methylation with histone acetylation. These modifications differ fundamentally in their chemical effects and functional consequences. Acetylation adds an acetyl group to lysine, neutralizing the positive charge and weakening histone-DNA interactions, which generally leads to a more open chromatin structure and transcriptional activation. Methylation does not change the charge of the residue; it creates a hydrophobic patch that is recognized by specific reader proteins. Methylation can be activating or repressive depending on the residue and methylation state, whereas acetylation is almost always associated with activation.

Additionally, acetylation is a binary modification (a lysine is either acetylated or not), while methylation has three possible states (me1, me2, me3) for lysine and three configurations for arginine. The enzymes are also distinct: Histone Acetyltransferase and Histone Deacetylase add and remove acetyl groups, while methyltransferases and demethylases handle methylation.

Context-Dependent Effects

Another common misconception is that a given methylation mark always has the same effect. H3K4me3 is activating at promoters but can be repressive when present at enhancers in certain contexts. H3K9me3 is repressive at heterochromatin but H3K9me1 is activating at gene bodies. The same mark can recruit different readers depending on the presence of neighboring modifications, the cell type, and the developmental stage. Students should avoid memorizing "methylation = activation" or "methylation = repression" and instead learn the specific marks and their contexts.

A related error is assuming that all methylation at a given residue has the same effect. H3K27me1 is activating, H3K27me2 is broadly distributed and repressive, and H3K27me3 is the canonical Polycomb mark. These states are deposited and removed by different enzymes and have different biological functions.

Students also often confuse the direction of regulation: they may state that H3K27me3 "causes" gene silencing when in fact it is one component of a complex regulatory system that includes DNA methylation, chromatin remodeling, and transcription factor binding. The mark is necessary but not always sufficient for repression.

Finally, a frequent experimental pitfall is the assumption that antibody specificity is absolute. Many anti-methyl-histone antibodies cross-react with other marks, particularly between H3K9me3 and H3K27me3, which share similar epitopes. Validation by peptide competition assays or mass spectrometry is essential before drawing conclusions from antibody-based experiments.

Frequently Asked Questions

What are the types of histone methylation?

Histone methylation occurs on lysine and arginine residues. Lysine can be monomethylated (me1), dimethylated (me2), or trimethylated (me3). Arginine can be monomethylated (MMA), asymmetrically dimethylated (aDMA), or symmetrically dimethylated (sDMA). Major lysine sites include H3K4, H3K9, H3K27, H3K36, H3K79, and H4K20. Major arginine sites include H3R2, H3R8, H3R17, and H4R3.

What is the process of histone methylation?

Histone methylation is the covalent transfer of methyl groups from the cofactor S-adenosylmethionine (SAM) to the nitrogen atoms of lysine or arginine side chains on histone proteins. The reaction is catalyzed by histone methyltransferases (HMTs). The process is reversible, with demethylases removing methyl groups.

What is an example of histone methylation?

A well-studied example is H3K4me3, which is enriched at the promoters of actively transcribed genes. It is deposited by the MLL family of methyltransferases and recognized by PHD finger-containing proteins such as TAF3, which helps recruit the transcription initiation machinery.

How does histone methylation affect gene expression?

Histone methylation affects gene expression primarily by recruiting effector proteins that recognize specific methylated marks. For example, H3K4me3 recruits transcriptional activators, while H3K27me3 recruits Polycomb repressive complexes. Methylation can also influence chromatin compaction directly, although this effect is generally weaker than for acetylation.

What is the mechanism of histone methylation?

The mechanism is an SN2 nucleophilic substitution. The deprotonated amino group of lysine (or the guanidinium group of arginine) attacks the methyl carbon of SAM, transferring the methyl group and releasing S-adenosylhomocysteine (SAH). SET domain enzymes and DOT1L use this mechanism with different active site architectures.

What enzymes add and remove histone methylation?

Methyltransferases add methyl groups: SET domain enzymes (e.g., MLL for H3K4, SUV39 for H3K9, EZH2 for H3K27, SETD2 for H3K36) and DOT1L for H3K79. Demethylases remove them: LSD1 (FAD-dependent, removes H3K4me1/2 and H3K9me1/2) and the JmjC family (Fe(II)- and α-ketoglutarate-dependent, remove all methylation states from various residues).

Is histone methylation permanent?

No. Although histone methylation is more stable than acetylation, it is enzymatically reversible. Demethylases such as LSD1 and the JmjC family remove methyl groups. Some methylation marks, particularly H3K9me3 at heterochromatin, can be maintained through cell divisions, but they are still subject to active removal under appropriate conditions.

What is the difference between histone methylation and acetylation?

Acetylation adds an acetyl group to lysine, neutralizing its positive charge and generally promoting open chromatin and transcriptional activation. Methylation adds methyl groups without changing the charge, and its effects depend on the specific residue and methylation state. Acetylation is binary (on/off), while methylation has multiple states. Acetylation is added by HATs and removed by HDACs; methylation is added by HMTs and removed by HDMs.

Key Takeaways

Histone methylation occurs on lysine (me1, me2, me3) and arginine (MMA, aDMA, sDMA) residues and does not alter the charge of the amino acid.
The functional outcome of methylation depends on the specific residue, the methylation state, and the genomic context; it can be activating (e.g., H3K4me3, H3K36me3) or repressive (e.g., H3K9me3, H3K27me3).
Methylation is written by histone methyltransferases (SET domain enzymes and DOT1L) using SAM as the methyl donor and erased by demethylases (LSD1 and JmjC family).
Methylation exerts its effects primarily through reader proteins that recognize specific marks and recruit chromatin remodeling complexes, transcription factors, or repressive complexes.
The Histone Code hypothesis describes how combinations of marks, including methylation, acetylation, and phosphorylation, coordinate gene regulation.
Histone methylation is essential for development, particularly in stem cell differentiation where bivalent domains poise genes for activation or repression.
Dysregulation of histone methylation enzymes is a hallmark of many cancers, and mutations in histone genes themselves can drive tumorigenesis.
ChIP-seq, mass spectrometry, and antibody-based assays are the primary methods for studying histone methylation, but each has limitations that must be carefully controlled.